Kornimate/medical-research-clean huggingface dataset:
feasibility of a social media-based weight loss program for low socioeconomic status individuals

Conditions: Obesity

Summary: the purpose of this study is to see if it is practical to use social media-based and traditional online weight loss intervention components among low socioeconomic status participants using the facebook social media (sm) and fitbit self-monitoring platforms. also, the study will test the effectiveness of recruiting participants via social media and at community events and locations. the results of this study will be used to inform future research studies.

the primary objectives of the proposed research are to: 1. assess the feasibility of social media-based (social support, social competition, and social rewards) and traditional online weight loss (education and goal setting) intervention components delivered to low-socioeconomic status (ses) participants using the facebook sm and fitbit self-monitoring platforms and 2. develop and assess methods for recruiting and retaining adequate numbers of low-ses participants for a future randomized controlled trial to assess the efficacy of an sm-based weight loss intervention. the study team will assess feasibility by conducting a 12-week pilot test of traditional and social media-based weight loss intervention components followed by qualitative and quantitative assessment with pilot participants. the specific aims are: aim 1- assess trial feasibility: the study team will assess intervention processes critical to the success of a larger efficacy trial during the 12-week pilot including: (1) participant recruitment and retention, (2) participant use of intervention components, (3) use of data collection strategies and instruments. aim 2 - assess intervention acceptability: the study team will conduct structured interviews and surveys among participants to assess participants' experience during the intervention. this study focuses on: (1) intervention design and content, (2) participant use of intervention technologies (facebook and fitbit), (3) participant concerns about privacy, and (4) barriers and facilitators to recruitment, retention, and participation. findings will be used to improve the design of a larger efficacy trial. study design: this study will employ a one group pre-post design.

Eligibility criteria:
inclusion criteria: * able to speak english * regular access to an internet-enabled device that can be synched with the fitbit wristband * body mass index (bmi) 25-40 kg/m\^2 * \< 30 minutes per day of self-reported moderate or vigorous physical activity * considered eligible for ohio expanded food and nutrition education program (efnep) income guidelines * located in the greater cleveland metropolitan area * not pregnant or planning on becoming pregnant * answers 'no' to all questions on the pa readiness questionnaire (par-q) or is cleared in writing by a physician * does not have a recent history of alcohol or drug abuse or is in treatment * does not have schizophrenia exclusion criteria: * does not meet all inclusion criteria

Keywords: cancer weight-loss social media
augmented reality (ar): the future of "patient information leaflets

Conditions: Sarcoma; Breast Cancer; Cleft Lip and Palate; Surgical Flap

Summary: this project aims to assess a new type of augmented reality patient information leaflet, in order to demonstrate that it is a beneficial information resource to patients when facing the diagnosis of sarcoma, breast cancer or to explain difficult concepts such as cleft lip repair. there are no published studies on the use of ar in patient leaflets.

at present, the traditional approach to patient education regarding diseases such as a new cancer diagnosis, is the patient information leaflet. patient information leaflets often fail to convey the required medical information due to poor levels of literacy in the population, with 20% patients in the uk having the lowest level of adult literacy (equivalent to an individual who is unable to determine how much medicine to give a child from information printed on the package). "health literacy" - the ability to obtain, understand, act on and communicate health information - is even lower, with estimates that 40% of patients have inadequate levels of health literacy. additionally, there is a large knowledge gap between what doctors perceive patients understand about an illness, medication, or operation, and what patients actually comprehend and retain during consultation. the plethora of problems of inadequate information, poor health literacy and patient-doctor knowledge disconnect, may be addressed with an approach to patient information leaflets using a platform that is entirely simulative and visual, thereby overcoming the problem of health literacy. the study builds upon pilot work by this research team on patient leaflets using ar to aid in patient education, visualisation and retention of information (lo et al 2019).

Eligibility criteria:
inclusion criteria: * patients who have undergone reconstructive surgery * patients who are awaiting reconstructive surgery * patients with sarcoma * patients with breast cancer * patients with reconstructive flaps * patients with or parents of patients with cleft lip and palate * patients with dyslexia will be included exclusion criteria: * cannot speak or read english * blind/severely visually impaired

Keywords: patient information leaflet augmented reality
psychotherapy for patients with psoriasis: effects in quality of life

Conditions: Psoriasis

Summary: the aim of this study is to determine the benefits of individual psychotherapy on quality of life for people with psoriasis receiving medical treatment versus a control group (awaiting group) treated with medical treatment, without psychotherapy.

further investigations studies are needed to determine the efficacy of psychological interventions for people with psoriasis. the aim of this study is to determine the benefits of individual psychotherapy on quality of life for people with psoriasis receiving medical treatment versus a control group (awaiting group) treated with medical treatment, without psychotherapy. this is an experimental randomized trial with control group. quality of life, symptoms: pruritus, scaling and pain, distress and the illness will be measured before and after the intervention using psychological and quality of life questionnaires, and dermatological evaluations for 120 subjects. the investigators expect that the experimental group scores at the end of the psychotherapy program will be less than 4 points in visual analog scale (vas) for pruritus, scaling and pain. the dermatology quality of life index (dqli) expected to be less than 4 points from the initial score, and the patients are expected to present less than 7 points in hospital anxiety and depression scale (hads). the experimental group scores will be less than the control group for quality of life, symptoms and distress.

Eligibility criteria:
inclusion criteria: * men and women at least 18 years old at the time of selection. * subjects diagnosed with moderated or severe psoriasis. * subjects with a ≥ 10 punctuation in dlqi questionnaire. * subjects that are in dermatological treatment. * patients should be able to understand and communicate with the investigator. exclusion criteria: * subjects suffering from a serious concomitant illness. * subjects with a mental illness. * subjects who are performing psychiatric treatment. * subjects who are performing psychotherapy sessions both individual and group. * patients who have alcohol dependence or drug abuse. * subjects that present legal incapacity or limited legal capacity. * subjects presenting illiteracy or language barriers.

Keywords: quality of life psychotherapy psoriasis treatments
the effect of musical video with virtual reality goggles on patient's anxiety and comfort during ureteroscopy

Conditions: Ureteroscopy; Operation Time; Music Listening

Summary: the effect of musical video with virtual reality goggles on patient's anxiety and comfort during ureteroscopy

ureteroscopy is a surgical procedure used diagnostically or therapeutically in urology. eliminating the patient's fear, anxiety and worry in the preoperative period is necessary to reduce the surgical stress response seen during the surgical procedure and to ensure normal physiological functions after surgery, early mobilization and patient comfort. when the patient is taken into surgery, reassuring and gentle communication should be established to reduce the patient's anxiety. for this reason, it is important that the surgical team members feel that they are with the patient and make the patient feel that they are with them. music is an art that organizes sounds in a way that provides a feeling of happiness. it can help the patient cope with all aspects of the disease; it improves physical, emotional, social and spiritual well-being and can help control and reduce pain and/or agitation. studies examining the relationship between music and depression and anxiety, it was found that depression and anxiety scores were significantly lower in the music therapy group compared to the control group. the aim of this study was to examine the effect of virtual reality goggles and musical video playback on the patient's operating room anxiety and comfort during ureteroscopy. the hypotheses that there is no difference in anxiety and comfort levels in the intervention and control groups after music intervention will be tested.

Eligibility criteria:
inclusion criteria: * being able to speak and understand turkish * being open to communication * being literate * being over 18 years of age * having a glasgow coma scale score of 13 and above exclusion criteria: * visual and hearing impairment * previous surgery * being a healthcare personnel * general anesthesia of the patient

Keywords: ureteroscopy music therapy virtual reality anxiety comfort
the effect of intravitreal avastin on the retina measured by electroretinogram

Conditions: Macular Degeneration

Summary: to evaluate the scotopic and photopic erg responses before and after one month of intravitreal avastin injection in patients with choroidal neovascularization. a positive finding that will reveal a toxic effect of intravitreal avastin injection on any component of the retina will have a significant important clinical impact regarding the decision whether the benefit of avastin treatment for cnv will prevail over toxic effect.

the study will include 20 patients who are diagnosed with cnv and were submitted for intravitreal injection of avastin. patients with uncontrolled glaucoma, any ocular operation two months prior to the injection, ocular inflammatory disease, systemic hypertension treated with more than one medication, myocardial infarct, congestive heart disease will not be included in the study. after the patient will approve to participate in the study and will fall in with the inclusion and exclusion criteria, the patient will sign a written consent statement (enclosed). medical history and ophthalmic examination will be written in the study file. the patients will undergo the full-field erg test using the iscev protocol. since the erg is a non invasive test the patient will be admitted on the same day for intravitreal avastin in the designated eye. after one month the patient will undergo identical erg protocol in addition to the standard follow-up examinations protocol for intravitreal avastin injection (1 day, 1 week, 1 month). the other eye will serve as control group.

Eligibility criteria:
inclusion criteria: 1. patients who were diagnosed with cnv caused by armd 2. erg can be performed in both eyes exclusion criteria: 1. treatment within 7 days with vertoprofin 2. treatment within one month with laser photocoagulation 3. ocular surgery for amd (besides laser). 4. participation in other medical study 5. sub-fovea rpe atrophy in the study eye. 6. cnv with ocular histoplasmosis, trauma, pathological myopia. 7. uveitis or history of uveitis. 8. retinal pigment epithelium tear in the fovea of the injected eye. 9. vitreous hemorrhage 10. conjunctivitis, keratitis, scleritis, endophthalmitis. 11. intraocular surgery (including cataract) within two months 12. uncontrolled glaucoma (iop≥30 mmhg under glaucoma medications) 13. hypertension treated with two or more medication 14. history of myocardial infarct 15. history of myocardial insufficiency -
the efficacy of amino acid supplementation in treating environmental enteric dysfunction among children at risk of malnutrition

Conditions: Amino Acid, Stunting, Environmental Enteric Dysfunction

Summary: a randomised controlled open label clinical trial to determine whether addition of indispensable amino acids (iaa) to standard complementary food will reduce occurrence of environmental enteric dysfunction (eed) compared with provision of standard complementary food without iaa in healthy malawian children aged 18-36 months with or without stunting.


Eligibility criteria:
inclusion criteria: * all children identified from the mangochi dss whose guardian/parent desires screening will be eligible for screening. this will first include age, weight, length, and muac assessment. if a participant meets age and anthropometric criteria, they will be invited to undergo full inclusion/exclusion criteria assessment, consent, and randomization. in order to be eligible to participate in the study, an individual must meet all of the following criteria: 1. 18-36 months old (now agreed to by all countries) 2. stunted (laz\&lt;-2) 3. of either sex 4. able and willing to undergo hiv testing 5. parent, carer, or guardian able and willing to give written, informed consent 6. a positive hiv test result will not be an exclusion criterion. exclusion criteria: * an individual who meets any of the following criteria will be excluded from participation in this study: 1. under 18 months of age 2. over 36 months old 3. wasted (weight-for-length z-score less than -2) 4. overweight (weight-for-length z-score greater than 2) 5. have had diarrhea (by self-report) in the preceding month 6. sibling or twin of another participating study child (2 children of different families in the same household are both eligible) 7. have any underlying condition other than hiv, which in the opinion of the investigator would put the subject at undue risk of failing study completion or would interfere with analysis of study results
pilot study: cardiovascular events in high risk orthopedic surgical patients

Conditions: Coronary Artery Disease; Cerebral Vascular Disease; Peripheral Artery Disease; Renal Insufficiency; Diabetes; COPD; Hypertension; Active Smoker; Cancer; CHF; Prior DVT/PE

Summary: this is a non-randomized, non-interventional pilot observational study designed to follow high-risk patients through their surgical and hospital stay. the investigators will collect 2 4ml vial's of blood (total of 8ml) prior to surgery to assess cv biomarkers - inflammatory, metabolic, hypercoagulable and platelet.

this study is primarily an observational pilot study. after identifying patients as high-risk according to the following criteria: cad and/or cvd and/or pad and/or \>=60 years old and at least 2 of the following - renal insufficiency, diabetes, copd, hypertension, active smoker (or active within 6 months of consent), cancer, congestive heart failure, or any blood clot - they will be asked to sign a consent form. patients surgical and hospital course will continue as per standard of care. prior to surgery, 8ml of blood will be collected for to assess cardiovascular biomarkers including inflammatory, metabolic, hypercoagulable and platelet biomarkers to be tested independently in dr. berger's lab in smilow. study staff will perform electrocardiograms on pod 2. results of these ecgs will not be placed in the patients' charts. no other procedures will be done for research purposes only.

Eligibility criteria:
inclusion criteria: * • ≥ 21 years of age * subjects undergoing open orthopedic surgery of the hip, knee or spine * high-risk subject cohort: * coronary artery disease (cad), or * cerebrovascular disease (cvd) (prior stroke, tia or carotid artery disease (\>70% stenosis), or * peripheral artery disease (pad), or * age ≥ 60 years and any 2 of the following: * renal insufficiency (creatinine clearance \< 60ml/min) * diabetes * chronic obstructive pulmonary disease (copd) * hypertension * active smoker or stopped less than 30 days prior to consent * cancer * congestive heart failure * prior blood clot exclusion criteria: * • severe co-morbid condition with life expectancy \< 6 months * inability to give informed consent or adhere to follow-up as per protocol
study of efficacy and safety of twice daily oral iptacopan (lnp023) in adult pnh patients who are naive to complement inhibitor therapy

Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH)

Summary: the purpose of this phase 3 study was to determine whether iptacopan is efficacious and safe for the treatment of paroxysmal nocturnal hemoglobinuria (pnh) patients who were naïve to complement inhibitor therapy.

this study was a multicenter, single-arm, open-label trial which was comprised of 8 weeks screening period, 24-week core treatment period and 24-week extension treatment period. eligible pnh patients with hemolysis (ldh \> 1.5 uln) and anemia (hemoglobin \<10 g/dl), who were naive to complement inhibitor therapy, including anti-c5 antibody treatment, received iptacopan monotherapy at a dose 200 mg orally b.i.d.

Eligibility criteria:
inclusion criteria: * male and female participants ≥ 18 years of age with a diagnosis of pnh confirmed by high-sensitivity flow cytometry with rbcs and wbcs clone size ≥ 10% * mean hemoglobin level \<10 g/dl * ldh \> 1.5 x upper limit of normal (uln) * vaccination against neisseria meningitidis infection is required prior to the start of study treatment * if not received previously, vaccination against streptococcus pneumoniae and haemophilus influenzae infections should be given exclusion criteria: * prior treatment with a complement inhibitor, including anti-c5 antibody * known or suspected hereditary complement deficiency * history of hematopoietic stem cell transplantation * patients with laboratory evidence of bone marrow failure (reticulocytes \<100x109/l; platelets \<30x109/l; neutrophils \<0.5x109/l). * active systemic bacterial, viral (incl. covid-19)or fungal infection within 14 days prior to study drug administration. * history of recurrent invasive infections caused by encapsulated organisms, e.g. meningococcus or pneumococcus. * major concurrent comorbidities including but not limited to severe kidney disease (e.g., dialysis), advanced cardiac disease (e.g., nyha class iv heart failure), severe pulmonary disease (e.g., severe pulmonary hypertension (who class iv)), or hepatic disease (e.g., active hepatitis) that in the opinion of the investigator precludes participant's participation in the study.

Keywords: paroxysmal nocturnal hemoglobinuria hemoglobin anemia lnp023 iptacopan
medication development in alcoholism: acamprosate versus naltrexone

Conditions: Alcoholism

Summary: the purpose of this study is to develop and validate a human laboratory model for prediction of medication efficacy in clinical trials for relapse prevention in alcohol dependence.

this is a double-blind, 3-cell, outpatient human laboratory study to determine the degree to which acamprosate and naltrexone will suppress subjective and physiological responsivity to alcohol cues relative to placebo in early abstinence.

Eligibility criteria:
inclusion criteria: * males or females ≥ 18 and ≤ 55 years of age * meets diagnostic and statistical manual-fourth edition (dsm-iv) criteria for current alcohol dependence * does not desire treatment * alcohol free, as verified by breath alcohol concentration, with a clinical institute withdrawal assessment (ciwa) ≤ 8, at the time of testing, with no evidence of drinking for at least 3 days but no more than 7 days prior to the cue reactivity session * able to complete and understand questionnaires and study procedures in english * verbal i.q. estimate ≥ 85 * signed informed consent exclusion criteria: * currently meets dsm-iv criteria for dependence on substances other than alcohol or nicotine * significant medical disorders that will increase potential risk or interfere with study participation * sexually active women with childbearing potential who are pregnant, nursing, or refuse to use a reliable method of birth control * meets dsm-iv criteria for a major axis i disorder, including depression or anxiety disorders * treatment within the month prior to screening with investigational medications or those which may influence drinking outcome, e.g., disulfiram (antabuse), naltrexone (revia), acamprosate (campral), antidepressants or other psychotropic agents * chronic treatment with any narcotic-containing medications during the previous month or evidence of current opiate use * liver function tests more than three times normal or elevated bilirubin * no fixed domicile and/or no availability by telephone or beeper * current involvement in or plans for treatment prior to study completion * patients who have a history of adverse drug reactions to the study drugs or their ingredients * failure to take double-blind medication as prescribed * inability to understand or comply with the provisions of the protocol or consent form
mri markers of cartilage damage in knee with osteoarthritis

Conditions: Osteoarthritis, Knee

Summary: the objectives of this study are: to identify and develop techniques to minimize precision errors in magnetic resonance imaging (mri) evaluation of knee cartilage, and to determine if results from newly-identified mri techniques in measuring cartilage changes and structure can be reproduced.

the development of a disease modifying osteoarthritis drugs (dmoads) is currently limited by the inability to detect and monitor early cartilage damage that would be amenable to treatment. there is growing interest within the pharmaceutical and research community to use magnetic resonance imaging (mri) to identify biochemical and structural changes in the cartilage extra cellular matrix that occur early in the disease process. although these techniques have been validated in small studies at single sites, multi-center evaluation of accuracy and precision, needed to apply these techniques to clinical trials of dmoads, has not been performed. to address this need, the primary objective for this protocol is to identify and develop techniques to minimize systematic errors that decrease precision of mri evaluation of knee cartilage, and to assess the reproducibility of the newly identified mri techniques in measuring the cartilage morphometry and structure. successful completion of this project may establish a multi-center imaging network in pennsylvania for mri evaluation of potential disease modifying osteoarthritis drugs (dmoads) therapy.

Eligibility criteria:
inclusion criteria: * participants must be \>18 years old; * participants must have a kl score between 0 and 3; * participants must have clearance to use protocol specified equipment: 3t mri with parallel imaging capability and phased array knee coil (minimum 4 elements); * participant had no change of treatment occur within the last 6 months; * participants have no plans of changing to a different treatment within the next 3 months; * participant must provide a study-specific signed informed consent form. exclusion criteria: * patients with contraindication to 3t mri: claustrophobia, implanted metal or medical device that is not approved for mri scanning at 3t, pregnancy, inability to tolerate relative immobility for 1 hour; * patients with prior knee surgery or trauma of the knee; * patients with kl score of 4.

Keywords: osteoarthritis knee magnetic resonance imaging knee cartilage reproducibility